Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.82 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.82 |
| ▸ | DRD2 | P14416 | 4/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29746339 | 1.00 | ESR1 (0.82) | ESR1ESR2DRD2DRD4DRD1 | |
| SCHEMBL10534351 | 0.84 | ESR1 (0.59) | ESR1ESR2KDM4EMEN1GLA | |
| SCHEMBL19284521 | 0.84 | ESR1 (0.63) | ESR1ESR2DRD2DRD4KDM4E | |
| SCHEMBL29745994 | 0.81 | ESR1 (0.55) | ESR1ESR2DRD1KDM4EMEN1 | |
| SCHEMBL26613390 | 0.81 | ESR1 (0.55) | ESR1ESR2DRD1KDM4EMEN1 | |
| SCHEMBL26613393 | 0.81 | ESR1 (0.55) | ESR1ESR2KDM4EMEN1GLA | |
| SCHEMBL26613451 | 0.81 | ESR1 (0.55) | ESR1ESR2DRD2KDM4EMEN1 | |
| SCHEMBL29746002 | 0.81 | ESR1 (0.55) | ESR1ESR2KDM4EMEN1GLA | |
| SCHEMBL26613534 | 0.81 | ESR1 (0.55) | ESR1ESR2KDM4EMEN1GLA | |
| Hydrochloric Acid SCHEMBL31384915 | 0.80 | ESR1 (0.54) | ESR1ESR2DRD1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083723-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | TORAY INDUSTRIES, INC. (JP) | 2026-03-26 | — | — | US | disclosed |
| US-12570639-B2 | Tetrahydroquinoline derivative and medicinal use thereof | TORAY INDUSTRIES, INC. (JP) | 2026-03-10 | — | — | US | disclosed |
| EP-4545079-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | Toray Industries, Inc. (JP) | 2025-04-30 | — | — | EP | disclosed |
| US-20240116903-A1 | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2024-04-11 | — | — | US | disclosed |
| WO-2023249105-A1 | THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR DRUG-INDUCED MYOCARDIAL DISORDERS | 東レ株式会社 | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249106-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | 東レ株式会社 | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249107-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR PERIPHERAL NERVE DISORDER | 東レ株式会社 | 2023-12-28 | — | — | WO | disclosed |
| EP-4269392-A1 | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF | Toray Industries, Inc. (JP) | 2023-11-01 | — | — | EP | disclosed |
| EP-4269392-A1 | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF | Toray Industries, Inc. (JP) | 2023-11-01 | — | — | EP | disclosed |
| CN-116648245-A | Tetrahydroquinoline derivative and medical application thereof | 东丽株式会社 | 2023-08-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116903-A1 | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF | AIFM2, TXNRD2, NFE2L2 | ESR1 3731/4885ESR2 1215/4885DRD2 2868/4885 |
| US-20260083723-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | AIFM2, GPX1, SOD1 | ESR1 3396/4885ESR2 860/4885DRD2 3623/4885 |
| US-12570639-B2 | Tetrahydroquinoline derivative and medicinal use thereof | AIFM2, GPX1, GPX4 | ESR1 3178/4885ESR2 411/4885DRD2 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.